Filing Flows › Myriad Genetics (MYGN) › Q1 2025
Myriad Genetics (MYGN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Myriad Genetics (MYGN) reported revenue of $196M for the first quarter 2025 (Q1 2025), -3% from a year earlier and -7% from the quarter before. Operating margin was -14.8%, net loss $100K (0.1% of revenue).
Myriad Genetics, Q1 2025: revenue $196M (-3% year over year), operating margin -14.8%, net loss $100K, operating cash flow −$16.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $196M | -7% | -3% |
| Operating profit | −$29.0M | — | — |
| Net earnings | −$100K | — | — |
| Operating cash flow | −$16.3M | — | — |
What changed
Revenue was $195.9M in Q1 2025, down 3% year over year and down 7% from the previous quarter. Hereditary Cancer was the largest line at 44% of revenue. Pharmacogenomics lost $7.9M year over year (down 20%), 125% of the total change.
Gross margin was 68.5%, up 0.5 points from a year earlier. Operating costs exceeded revenue by $29.0M, an operating margin of -14.8%. Operating expenses fell 1% while revenue fell 3%. The fastest-growing cost line was Research & development (+10%). The quarter ended with a net loss of $100K, narrower than the previous quarter's $42.5M loss. Net interest and other expense of $400K was the main reason.
Operating cash flow was −$16.3M. Non-cash charges added back $14.4M of depreciation and amortization and $9.5M of share-based compensation. Working capital and other items used $40.1M. Capital expenditures of $5.3M exceeded it, leaving free cash flow of −$21.6M.
Questions
What was Myriad Genetics' revenue in the first quarter 2025?
Myriad Genetics (MYGN) reported revenue of $196M for the first quarter 2025 (Q1 2025), -3% from a year earlier and -7% from the quarter before.
Was Myriad Genetics profitable in the first quarter 2025?
Operating loss was $29.0M (-14.8% of revenue) and net loss $100K.
Source: Myriad Genetics 10-Q on SEC EDGAR.